G. Guetens

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

M. Piccart, A. Awada, R. Maes, 2006 .

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

B Landuyt, H. Wildiers, A. V. van Oosterom, 2003, British Journal of Cancer.

Melphalan availability in hypoxia‐inducible factor‐1α+/+ and factor‐1α–/– tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport

M. Highley, H. Wildiers, A. V. van Oosterom, 2002, International journal of cancer.

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

A. V. van Oosterom, E. D. de Bruijn, R. Maes, 2007, Anti-cancer drugs.